Alpha Tau to Present at the J.P. Morgan 2026 Healthcare Conference
Rhea-AI Summary
Alpha Tau (NASDAQ: DRTS) will present a corporate overview and update at the J.P. Morgan 2026 Healthcare Conference on January 15, 2026 at 11:15am PT / 2:15pm ET in San Francisco.
CEO Uzi Sofer and CFO Raphi Levy will review recent achievements and the outlook for upcoming data milestones, and will host institutional 1-on-1 investor meetings. The presentation runs 11:15am–11:55am PT at Westin St. Francis. A webcast link will be posted on the company’s Events & Presentations page.
Positive
- None.
Negative
- None.
News Market Reaction – DRTS
In the Dec 18 session, DRTS gained 4.16%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 09 | GBM trial update | Positive | +8.7% | First U.S. GBM patient treated with Alpha DaRT in pilot study. |
| Dec 04 | ASCO GI abstracts | Positive | +4.6% | Two pancreatic cancer Alpha DaRT abstracts accepted for ASCO GI 2026. |
| Dec 02 | FDA IDE approval | Positive | +2.4% | FDA IDE approval to start pilot study in recurrent prostate cancer. |
| Dec 01 | Investor conferences | Neutral | -4.8% | December investor conference appearances and 1x1 meeting availability. |
| Nov 20 | Q3 2025 earnings | Negative | -5.7% | Q3 results with higher net loss and increased R&D spending. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Positive clinical and regulatory updates have generally coincided with positive price reactions, while earnings and conference-related news saw weaker or negative moves.
Recent news for Alpha Tau highlights ongoing clinical expansion and regulatory progress. On Nov 20, Q3 2025 results showed increased R&D spending and a larger $30.5M nine‑month net loss, which was followed by a -5.71% move. Subsequent December announcements covered new prostate cancer IDE approval, ASCO GI pancreatic abstracts, and first GBM patient treatment, all with positive price reactions. An investor conference participation release on Dec 1 coincided with a -4.79% move, showing more mixed reactions to non-clinical catalysts.
Key Terms
alpha-radiation medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- The overview presentation will review some of the Company’s recent achievements as well as the outlook for upcoming data milestones -
JERUSALEM, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CEO Uzi Sofer and CFO Raphi Levy will present a corporate overview and update at the J.P. Morgan 2026 Healthcare Conference on Thursday, January 15, 2026 at 11:15am PT / 2:15pm ET, in San Francisco, CA, and will host institutional investor meetings at the event.
| Event: | J.P. Morgan 2026 Healthcare Conference |
| Format: | Presentation and 1-on-1 Meetings |
| Date: | January 15, 2026 |
| Time: | 11:15AM PT – 11:55AM PT |
| Location: | Westin St. Francis, San Francisco, CA |
Webcast: Link will be posted on the “Events & Presentations” page in the Investor Relations section on the Company’s website at https://www.alphatau.com/events
Please reach out to your J.P. Morgan representative to schedule 1-on-1 meetings with Mr. Sofer and Mr. Levy.
About Alpha Tau Medical Ltd.
Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.
About Alpha DaRT ®
Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.
Investor Relations Contact:
IR@alphatau.com
